Researchers at McMaster University and MIT have leveraged generative artificial intelligence to pioneer enterololin, a novel narrow-spectrum antibiotic designed to selectively target pathogenic Enterobacteriaceae linked to inflammatory bowel disorders. This AI-driven discovery exemplifies cutting-edge computational drug design expediting identification of therapeutics with enhanced specificity and efficacy. This milestone highlights the growing role of AI in addressing antimicrobial resistance and complex disease management by predicting molecular targets and mechanisms ahead of experimental validation.